{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T15:52:29Z","timestamp":1679759549426},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T00:00:00Z","timestamp":1478476800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Amgen Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s12032-016-0850-9","type":"journal-article","created":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T08:18:57Z","timestamp":1478506737000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin\u2019s lymphoma (NHL) and granulocyte-colony\u00a0stimulating factors (G-CSF) as observed in clinical practice in Italy"],"prefix":"10.1007","volume":"33","author":[{"given":"Umberto","family":"Vitolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Angrili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"DeCosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Wetten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,7]]},"reference":[{"key":"850_CR1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2014","unstructured":"Ferlay J, Soerjomataram II, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"850_CR2","first-page":"85","volume":"38","author":"The Italian Association of Cancer Registries (AIRTUM)","year":"2014","unstructured":"The Italian Association of Cancer Registries (AIRTUM). Prevalence and cure of cancer in Italy: non-Hodgkin lymphoma. Epidemiol Prev. 2014;38:85.","journal-title":"Epidemiol Prev"},{"key":"850_CR3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mds517","volume":"24","author":"M Ghielmini","year":"2013","unstructured":"Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, et al. ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24:561\u201376.","journal-title":"Ann Oncol"},{"key":"850_CR4","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin\u2019s lymphomas [V2.2015]. 2015 [cited 2015 May 21]. http:\/\/www.nccn.org ."},{"key":"850_CR5","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/cncr.11827","volume":"98","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003;98:2402\u20139.","journal-title":"Cancer"},{"key":"850_CR6","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s00520-008-0430-4","volume":"16","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer. 2008;16:1299\u2013309.","journal-title":"Support Care Cancer"},{"key":"850_CR7","first-page":"440","volume":"1","author":"DC Dale","year":"2003","unstructured":"Dale DC, McCarter GC, Crawford J, Lyman GH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. JNCCN. 2003;1:440\u201354.","journal-title":"JNCCN"},{"key":"850_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8\u201332.","journal-title":"Eur J Cancer"},{"key":"850_CR9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228\u201337.","journal-title":"Cancer"},{"key":"850_CR10","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"GH Lyman","year":"2010","unstructured":"Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116:5555\u201363.","journal-title":"Cancer"},{"key":"850_CR11","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258\u201366.","journal-title":"Cancer"},{"key":"850_CR12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3111\/13696998.2013.782034","volume":"16","author":"B Dulisse","year":"2013","unstructured":"Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, et al. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ. 2013;16:720\u201335.","journal-title":"J Med Econ"},{"key":"850_CR13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00520-011-1306-6","volume":"20","author":"R Pettengell","year":"2012","unstructured":"Pettengell R, Johnsen HE, Johnson HE, Lugtenburg PJ, Silvestre AS, D\u00fchrsen U, et al. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer. 2012;20:647\u201352.","journal-title":"Support Care Cancer"},{"key":"850_CR14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00277-008-0447-2","volume":"87","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol. 2008;87:429\u201330.","journal-title":"Ann Hematol"},{"key":"850_CR15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","volume":"7","author":"GH Lyman","year":"2009","unstructured":"Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Comp Cancer Netw. 2009;7:99\u2013108.","journal-title":"J Natl Comp Cancer Netw"},{"key":"850_CR16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00520-014-2459-x","volume":"23","author":"SC Miguel de","year":"2015","unstructured":"de Miguel SC, Calleja-Hern\u00e1ndez M\u00c1, Menj\u00f3n-Beltr\u00e1n S, Vallejo-Rodr\u00edguez I. Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia. Support Care Cancer. 2015;23:547\u201359.","journal-title":"Support Care Cancer"},{"key":"850_CR17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol. 2010;21:248\u201351.","journal-title":"Ann Oncol"},{"key":"850_CR18","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myeloid growth factors [v.2.2014]. 2014. www.nccn.org ."},{"key":"850_CR19","unstructured":"Associazione Italiana di Oncologia Medica (AIOM). Linee guida\u2014Gestione della tossicita\u2019 ematopoietica in Oncologia. 2014 [cited 2015 May 17]. www.aiom.it ."},{"key":"850_CR20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105\u201316.","journal-title":"Lancet Oncol"},{"key":"850_CR21","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1634\/theoncologist.12-12-1416","volume":"12","author":"L Balducci","year":"2007","unstructured":"Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12:1416\u201324.","journal-title":"Oncologist"},{"key":"850_CR22","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1182\/blood-2002-10-3238","volume":"101","author":"E Osby","year":"2003","unstructured":"Osby E, Hagberg H, Kval\u00f8y S, Teerenhovi L, Anderson H, Cavallin-Stahl E, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic lymphoma group randomized trial. Blood. 2003;101:3840\u20138.","journal-title":"Blood"},{"key":"850_CR23","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","volume":"116","author":"M Pfreundschuh","year":"2010","unstructured":"Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood. 2010;116:5103\u201310.","journal-title":"Blood"},{"key":"850_CR24","unstructured":"Amgen Europe B.V. Neupogen\u00ae (filgrastim) summary of product characteristics (Granulokine\u00ae is the Italian brand name for Neupogen\u00ae). [cited 2015 May 17]. www.mhra.gov.uk ."},{"key":"850_CR25","unstructured":"Chugai Pharma UK Ltd. Granocyte\u00ae (lenograstim) summary of product characteristics. [cited 2015 May 17]. www.mhra.gov.uk ."},{"key":"850_CR26","unstructured":"Amgen Europe B.V. Neulasta\u00ae (pegfilgrastim) summary of product characteristics. 2014. www.ema.europa.eu ."},{"key":"850_CR27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40259-015-0127-4","volume":"29","author":"T Arvedson","year":"2015","unstructured":"Arvedson T, O\u2019Kelly J, Yang B-B, O\u2019Kelly J, Yang B-B. Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor. BioDrugs. 2015;29:185\u201398.","journal-title":"BioDrugs"},{"key":"850_CR28","unstructured":"European Medicines Agency. [cited 2015 Nov 15]. http:\/\/www.ema.europa.eu ."},{"key":"850_CR29","first-page":"2647","volume":"10","author":"J Hoggatt","year":"2015","unstructured":"Hoggatt J, Tate TA, Pelus LM. Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia. Int J Nanomed. 2015;10:2647\u201352.","journal-title":"Int J Nanomed"},{"key":"850_CR30","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3109\/10428194.2011.643407","volume":"53","author":"HE Johnsen","year":"2012","unstructured":"Johnsen HE, Haioun C, Lugtenburg PJ, Salar A, Jaeger U, Pettengell R, et al. Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14\u00a0days for diffuse large B-cell lymphoma in routine clinical practice. Leuk Lymphoma. 2012;53:982\u20134.","journal-title":"Leuk Lymphoma"},{"key":"850_CR31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.leukres.2012.02.002","volume":"36","author":"A Salar","year":"2012","unstructured":"Salar A, Haioun C, Rossi FG, Duehrsen U, Pettengell R, Johnsen HE, et al. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res. 2012;36:548\u201353.","journal-title":"Leuk Res"},{"key":"850_CR32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clml.2012.06.004","volume":"12","author":"P Lugtenburg","year":"2012","unstructured":"Lugtenburg P, Silvestre AS, Rossi FG, Noens L, Krall W, Bendall K, et al. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Clin Lymphoma Myeloma Leuk. 2012;12:297\u2013305.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"850_CR33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s12032-013-0797-z","volume":"31","author":"S Barni","year":"2014","unstructured":"Barni S, Lorusso V, Giordano M, Sogno G, Gamucci T, Santoro A, et al. A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. Med Oncol. 2014;31:797.","journal-title":"Med Oncol"},{"key":"850_CR34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.critrevonc.2010.02.002","volume":"77","author":"H Wildiers","year":"2011","unstructured":"Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol. 2011;77:221\u201340.","journal-title":"Crit Rev Oncol Hematol"},{"key":"850_CR35","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","volume":"22","author":"GH Lyman","year":"2004","unstructured":"Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin\u2019s lymphoma: a nationwide study. J Clin Oncol. 2004;22:4302\u201311.","journal-title":"J Clin Oncol"},{"key":"850_CR36","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1345\/aph.1G516","volume":"40","author":"D Weycker","year":"2006","unstructured":"Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40:402\u20137.","journal-title":"Ann Pharmacother"},{"key":"850_CR37","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2013;24:2475\u201384.","journal-title":"Ann Oncol"},{"key":"850_CR38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/1472-6963-14-189","volume":"14","author":"D Weycker","year":"2014","unstructured":"Weycker D, Barron R, Edelsberg J, Kartashov A, Legg J, Glass AG. Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Serv Res. 2014;14:189.","journal-title":"BMC Health Serv Res"},{"key":"850_CR39","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdp544","volume":"21","author":"S Luminari","year":"2010","unstructured":"Luminari S, Montanini A, Caballero D, Bologna S, Notter M, Dyer MJS, et al. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol. 2010;21:1492\u20139.","journal-title":"Ann Oncol"},{"key":"850_CR40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/1660.18158","volume":"100","author":"D Fagnani","year":"2014","unstructured":"Fagnani D, Isa L, Verga MF, Nova P, Casartelli C, Filipazzi V, et al. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study. Tumori. 2014;100:491\u20138.","journal-title":"Tumori"},{"key":"850_CR41","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","volume":"23","author":"L Wang","year":"2015","unstructured":"Wang L, Baser O, Kutikova L, Page JH, Barron R. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2015;23:3131\u201340.","journal-title":"Support Care Cancer"},{"key":"850_CR42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2015","unstructured":"Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer. 2015;23:525\u201345.","journal-title":"Support Care Cancer"},{"key":"850_CR43","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33:3199\u2013212.","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-016-0850-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-016-0850-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-016-0850-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T09:59:15Z","timestamp":1568541555000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-016-0850-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,7]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1007\/s12032-016-0850-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,7]]},"article-number":"139"}}